N/A
Completed N=603
Feasibility of Interventions on People Who Inject Drugs in Vietnam
HIV · Hepatitis Virus · Substance Abuse
Source: ClinicalTrials.gov NCT02573948 ↗
Enrolled (actual)
603
Serious AEs
3.6%
Results posted
Aug 2018
Primary outcomePrimary: Number of Cohort Participants Attending the Last Follow-up Visit at W52 — 194 Participants
Summary
This study aims at assessing the feasibility of implementing an interventional cohort of people who inject drugs in Haiphong, Viet Nam.
For this purpose, the investigators will conduct a RDS survey to i) assess the current situation of drug use behaviour, HIV and Hepatitis C Virus (HCV) infection in the study population and ii) recruit participants for the longitudinal phase. The latter will consist of enroling the most difficult to reach People Who Inject Drugs (PWID) (those not followed by health centers), including early injectors, Men who have Sex with Men (MSM) and female sex workers (FSW) and following them up for 6 months in order to estimate the follow-up rate and preliminary estimates of HIV and HCV incidence.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Cohort Participants Attending the Last Follow-up Visit at W52 |
194 | — |
| SECONDARY HCV Seroconversion |
18 | — |
| SECONDARY HIV Seroconversion |
— | — |
| SECONDARY Incidence of HCV Infection |
19.4 | — |
| SECONDARY HIV Incidence |
— | — |
Eligibility Criteria
- Inclusion criteria
- Being more than 18 years of age
- Being drug injector confirmed by a positive urine drug test with knowledge of injecting procedures
- Having signed the informed consent form
- For the Longitudinal study - having participated in the RDS survey
- Exclusion criteria
- Unable to understand informed consent and how to answer a questionnaire
- For the longitudinal study - being under methadone maintenance therapy and antiretroviral treatment
- Having a health condition not compatible with study follow-up
- Plan to move away from Haiphong in the next 2 years
- Serving a sentence in prison
Data sourced from ClinicalTrials.gov (NCT02573948). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.